-$0.17 EPS Expected for Agile Therapeutics Inc (AGRX) This Quarter

Wall Street brokerages expect Agile Therapeutics Inc (NASDAQ:AGRX) to post earnings per share (EPS) of ($0.17) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Agile Therapeutics’ earnings. The lowest EPS estimate is ($0.19) and the highest is ($0.16). Agile Therapeutics reported earnings per share of ($0.26) in the same quarter last year, which would suggest a positive year-over-year growth rate of 34.6%. The firm is expected to issue its next earnings report on Monday, November 5th.

On average, analysts expect that Agile Therapeutics will report full-year earnings of ($0.61) per share for the current financial year, with EPS estimates ranging from ($0.65) to ($0.56). For the next year, analysts forecast that the company will post earnings of ($0.70) per share, with EPS estimates ranging from ($0.94) to ($0.41). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that cover Agile Therapeutics.

Agile Therapeutics (NASDAQ:AGRX) last posted its quarterly earnings data on Friday, August 3rd. The specialty pharmaceutical company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01.

A number of equities analysts have recently weighed in on the stock. ValuEngine raised shares of Agile Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, August 3rd. Royal Bank of Canada cut their price objective on shares of Agile Therapeutics to $3.00 and set an “outperform” rating for the company in a research report on Monday, May 21st. Finally, HC Wainwright set a $4.00 price objective on shares of Agile Therapeutics and gave the company a “buy” rating in a research report on Monday, May 21st. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Agile Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $6.25.

In other news, insider Life Sciences Maste Perceptive sold 298,628 shares of the business’s stock in a transaction that occurred on Thursday, July 26th. The shares were sold at an average price of $0.30, for a total value of $89,588.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 7.30% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC grew its holdings in Agile Therapeutics by 76.3% in the second quarter. Renaissance Technologies LLC now owns 792,990 shares of the specialty pharmaceutical company’s stock valued at $392,000 after purchasing an additional 343,290 shares during the period. A.R.T. Advisors LLC grew its holdings in Agile Therapeutics by 82.3% in the first quarter. A.R.T. Advisors LLC now owns 66,426 shares of the specialty pharmaceutical company’s stock valued at $170,000 after purchasing an additional 29,995 shares during the period. Dimensional Fund Advisors LP grew its holdings in Agile Therapeutics by 62.8% in the first quarter. Dimensional Fund Advisors LP now owns 145,070 shares of the specialty pharmaceutical company’s stock valued at $373,000 after purchasing an additional 55,937 shares during the period. Franklin Resources Inc. grew its holdings in Agile Therapeutics by 17.0% in the first quarter. Franklin Resources Inc. now owns 3,355,200 shares of the specialty pharmaceutical company’s stock valued at $8,623,000 after purchasing an additional 487,400 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in Agile Therapeutics by 113.1% in the fourth quarter. Bank of New York Mellon Corp now owns 38,920 shares of the specialty pharmaceutical company’s stock valued at $105,000 after purchasing an additional 20,654 shares during the period. Hedge funds and other institutional investors own 69.79% of the company’s stock.

Shares of NASDAQ:AGRX remained flat at $$0.25 during trading on Thursday. 224,373 shares of the stock were exchanged, compared to its average volume of 492,618. The firm has a market capitalization of $8.77 million, a price-to-earnings ratio of -0.28 and a beta of 1.48. Agile Therapeutics has a twelve month low of $0.23 and a twelve month high of $5.40.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.

Read More: Trading Strategy

Get a free copy of the Zacks research report on Agile Therapeutics (AGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply